Does the development of oncology drugs meet clinical needs? Expert: Far from it!

(Health Times reporter Qiao Jingfang)
"For both doctors and patients, the development of Chinese cancer drugs is far from meeting clinical needs." On July 10, Professor Wang Wei of the Breast Center of Peking University People's Hospital said at the 2020 China Society of Clinical Oncology (CSCO) Annual Breast Cancer Conference and 2020 National Breast Cancer Conference.At the
meeting, Jiang Zefei, director of breast oncology at the Fifth Medical Center of the PLA General Hospital and chairman of the CSCO Breast Cancer Expert Committee, presided over a national line to discuss the opportunities and challenges facing breast cancer diagnosis and treatment, and contributed Chinese wisdom to breast cancer research and development.
the development of oncology drugs to meet clinical needs?
is far from satisfactory
Professor Wang Wei of the Breast Center at Peking University People's Hospital, says that many innovative drugs have been developed in China, which have brought many opportunities to Chinese patients. But "no best, only better" and we want more patients to be cured, so the development of Chinese oncologists is far from meeting clinical needs for both doctors and patients."We've really made a lot of progress in the development of oncologists over the years, but at the same time the clinical needs are growing, so it's really hard to meet these needs, "
. "Chinese Professor Wang Tao, A. Wang Tao, A. Mammography Department, Fifth Medical Center of the Civil Liberation Army General Hospital, agrees.
what further can cancer drugs be developed?
at least three aspects
from the current clinical point of view, Professor Wang Tao believes that the research and development of cancer drugs need to be strengthened in at least three aspects. The first is the development of new drugs, including some real new drugs, some special mechanisms of new drugs, etc. , we are still lacking in this area, need to strengthen;
on the review of cancer drugs, Xia Lin, a clinical judge at the Drug Review Center of the State Drug Administration, said that Since deepening the drug approval reform in 2016, China has made a lot of efforts to speed up the listing of new drugs. The Measures for the Administration of Drug Registration, which came into effect on July 1 this year, clearly establish a system for accelerating the listing of drugs to support clinical value-oriented drug innovation. For drugs in short supply and included in the breakthrough therapeutic drug program, drugs that meet the conditions approved may apply for the application of priority review and approval procedures to improve clinical accessibility when applying for a listing license.How does
drug development fit into patient needs?
Practice and Innovation
" China has published more than 200 studies and India has more than 20, but India's medical development is no worse than ours. Professor Liu Qiang, of the Breast Oncology Center at Sun Yat-sen Memorial Hospital, Zhongshan University, said that how to promote clinical transformation, you must first have your own original.
May this year, a study published in the Journal of Cancer Immunotherapy, including Professor Liu Jieqiong and Professor Liu Qiang of Sun Yat-sen Memorial Hospital of Sun Yat-sen University of Advanced Three-Negative Breast Cancer, confirmed the effectiveness and safety of the treatment of advanced three-negative breast cancer (TNBC) in a combination of two Chinese original drug combinations of non-chemotherapy: PD-1 antibody Karellizhu monoantiapicom endothelial cell growth factor receptor 2 (VEGFR-2) inhibitor apatinib.
, Wang Ning, Ph.D., of Lilly's department of medicine, believes that some studies have directly excluded some patients whose needs are difficult to meet. She suggests that researchers should find clinical problems in practice and solve them in innovative ways. For example, male breast cancer is a vulnerable group of breast cancer patients, and some enterprises to meet the needs of this group of people, to solve the confusion in the treatment, to explore a new direction of drug development. For example, multi-drug economics should also strengthen research, by experts comprehensive assessment, hoping to provide patients with efficacy and cost-effective drugs.
.